What's Inside

This special edition examines how MFN is changing the global drug pricing and access landscape. Through real-world examples, expert commentary, and early market signals, the report highlights how manufacturers and payers are adapting to protect value, ensure compliance, and maintain flexibility amid evolving policy and trade pressures.

The Global Impact of the MFN Executive Order

Understand how MFN is driving price alignment between the US and selected reference countries, and how its ripple effects are influencing international referencing frameworks and pricing strategies globally.

Market Examples and Early Trends

Explore examples from leading manufacturers illustrating how MFN-related pricing dynamics are influencing price adjustments, contracting strategies, and policy responses across markets.

Strategic Takeaways for Drug Manufacturers and Payers

Learn how pharma and payers are:
‍
✔ Assessing exposure and modeling risk under MFN and reference-pricing frameworks
✔ Expanding MEA adoption to preserve flexibility under policy pressure
✔ Establishing clear MEA governance to monitor outcomes, renewals, and compliance

Managed Entry Agreements Take Center Stage

See how Managed Entry Agreements (MEAs) are being used to manage volatility, protect value, and separate list from net prices under tighter transparency and compliance requirements.

Why It Matters

The MFN Executive Order and related pricing and reimbursement policies are redefining how countries evaluate value and set reimbursement benchmarks. This report helps you understand emerging trends, prepare for future policy shifts, and adapt with clarity, agility and confidence.